Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kintor PharmaceuticalKNTPF 24 Debt-to-Equity is 0.47 as of Dec. 2025, which is 104% above its 10-year median of 0.23. GuruFocus rates KNTPF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 968 Biotechnology companies, Kintor Pharmaceutical ranks worse than 73.97% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kintor Pharmaceutical's Debt-to-Equity or its related term are showing as below:
KNTPF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 0.23 Max: 0.55
Current: 0.47
During the past 8 years, the highest Debt-to-Equity Ratio of Kintor Pharmaceutical was 0.55. The lowest was 0.10. And the median was 0.23.
KNTPF's Debt-to-Equity is ranked worse than 73.97% of 968
companies
in the Biotechnology industry
Industry Median: 0.16
vs KNTPF: 0.47
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kintor Pharmaceutical Debt-to-Equity Related Terms
Kintor Pharmaceutical Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Kintor Pharmaceutical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNTPF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Kintor Pharmaceutical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical (KNTPF) has a Debt-to-Equity of 0.47 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kintor Pharmaceutical and its competitors. This is 104% above median its historical median of 0.23. Over the past decade, Kintor Pharmaceutical's Debt-to-Equity has ranged from 0.10 to 0.55. According to the industry distribution chart, Kintor Pharmaceutical ranks #716 out of 968 companies in the Biotechnology industry, placing it in the top 74%.
Is Kintor Pharmaceutical's Debt-to-Equity too high?
Kintor Pharmaceutical's current Debt-to-Equity of 0.47 is 104% above median its 10-year median of 0.23. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.55. The Biotechnology industry median Debt-to-Equity is 0.16. Kintor Pharmaceutical's value of 0.47 is 193.8% above this industry median. Based on the distribution chart, Kintor Pharmaceutical ranks #716 out of 968 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kintor Pharmaceutical has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #716 out of 968 companies for Debt-to-Equity. This places Kintor Pharmaceutical in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Kintor Pharmaceutical's value of 0.47 is 193.8% above this benchmark. Historically, Kintor Pharmaceutical's own Debt-to-Equity has ranged from 0.10 to 0.55 over the past decade. While the company's 10-year median is 0.23 vs. the industry median of 0.16, Kintor Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kintor Pharmaceutical's current Debt-to-Equity of 0.47 is 193.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kintor Pharmaceutical and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kintor Pharmaceutical's current Debt-to-Equity is 0.47, which is 104% above median its own 10-year median of 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Debt-to-Equity of 0.47. The current Debt-to-Equity is 0.47, which is 104% above median its 10-year median of 0.23 and 193.8% above the Biotechnology industry median of 0.16. Kintor Pharmaceutical's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Debt-to-Equity is 0.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
24GF Score
Get the complete analysis for KNTPF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 
